Free Trial
→ BUY THIS: Claim a backdoor stake in SpaceX (From Chaikin Analytics) (Ad)tc pixel Free WINT Stock Alerts

Windtree Therapeutics (WINT) Competitors

Windtree Therapeutics logo
$0.02 +0.00 (+28.57%)
As of 03:50 PM Eastern
Compare

WINT vs. VCNX, SLXN, CANF, ELAB, and IMCC

Should you buy Windtree Therapeutics stock or one of its competitors? MarketBeat compares Windtree Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Windtree Therapeutics include Vaccinex (VCNX), Silexion Therapeutics (SLXN), Can-Fite BioPharma (CANF), PMGC (ELAB), and IM Cannabis (IMCC). These companies are all part of the "pharmaceutical products" industry.

How does Windtree Therapeutics compare to Vaccinex?

Vaccinex (NASDAQ:VCNX) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Vaccinex's return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VaccinexN/A N/A -383.58%
Windtree Therapeutics N/A -207.34%-50.19%

In the previous week, Vaccinex's average media sentiment score of 0.00 equaled Windtree Therapeutics'average media sentiment score.

Company Overall Sentiment
Vaccinex Neutral
Windtree Therapeutics Neutral

Windtree Therapeutics has lower revenue, but higher earnings than Vaccinex. Vaccinex is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaccinex$388K6.77-$20.25M-$48.27N/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

Vaccinex has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by company insiders. Comparatively, 0.2% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Windtree Therapeutics beats Vaccinex on 5 of the 9 factors compared between the two stocks.

How does Windtree Therapeutics compare to Silexion Therapeutics?

Windtree Therapeutics (NASDAQ:WINT) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

29.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 10.9% of Silexion Therapeutics shares are owned by institutional investors. 0.2% of Windtree Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Silexion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Silexion Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Silexion Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
Silexion TherapeuticsN/AN/A-$11.91M-$80.50N/A

Windtree Therapeutics' return on equity of -207.34% beat Silexion Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
Silexion Therapeutics N/A -516.86%-176.68%

In the previous week, Silexion Therapeutics had 2 more articles in the media than Windtree Therapeutics. MarketBeat recorded 2 mentions for Silexion Therapeutics and 0 mentions for Windtree Therapeutics. Silexion Therapeutics' average media sentiment score of 1.92 beat Windtree Therapeutics' score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Windtree Therapeutics Neutral
Silexion Therapeutics Very Positive

Windtree Therapeutics has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, Silexion Therapeutics has a beta of -0.32, indicating that its share price is 132% less volatile than the broader market.

Summary

Windtree Therapeutics beats Silexion Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Windtree Therapeutics compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by insiders. Comparatively, 0.2% of Windtree Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Windtree Therapeutics has lower revenue, but higher earnings than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can-Fite BioPharma$405K4.59-$7.63M-$35.80N/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

Can-Fite BioPharma has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

Can-Fite BioPharma presently has a consensus target price of $42.50, suggesting a potential upside of 1,396.48%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, research analysts clearly believe Can-Fite BioPharma is more favorable than Windtree Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Windtree Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Can-Fite BioPharma's return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Can-Fite BioPharmaN/A N/A N/A
Windtree Therapeutics N/A -207.34%-50.19%

In the previous week, Can-Fite BioPharma's average media sentiment score of 0.00 equaled Windtree Therapeutics'average media sentiment score.

Company Overall Sentiment
Can-Fite BioPharma Neutral
Windtree Therapeutics Neutral

Summary

Can-Fite BioPharma beats Windtree Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Windtree Therapeutics compare to PMGC?

PMGC (NASDAQ:ELAB) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

PMGC has a beta of -0.27, meaning that its share price is 127% less volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market.

Windtree Therapeutics has lower revenue, but higher earnings than PMGC. PMGC is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PMGC$1.27M1.34-$7.75M-$168.62N/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

22.2% of PMGC shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 0.0% of PMGC shares are owned by insiders. Comparatively, 0.2% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PMGC
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Windtree Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

PMGC's return on equity of -117.82% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PMGCN/A -117.82% -70.79%
Windtree Therapeutics N/A -207.34%-50.19%

In the previous week, PMGC had 4 more articles in the media than Windtree Therapeutics. MarketBeat recorded 4 mentions for PMGC and 0 mentions for Windtree Therapeutics. PMGC's average media sentiment score of 0.47 beat Windtree Therapeutics' score of 0.00 indicating that PMGC is being referred to more favorably in the media.

Company Overall Sentiment
PMGC Neutral
Windtree Therapeutics Neutral

Summary

Windtree Therapeutics beats PMGC on 7 of the 12 factors compared between the two stocks.

How does Windtree Therapeutics compare to IM Cannabis?

Windtree Therapeutics (NASDAQ:WINT) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Windtree Therapeutics has higher earnings, but lower revenue than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
IM Cannabis$50.91M0.03-$8.10M-$1.75N/A

In the previous week, IM Cannabis had 3 more articles in the media than Windtree Therapeutics. MarketBeat recorded 3 mentions for IM Cannabis and 0 mentions for Windtree Therapeutics. IM Cannabis' average media sentiment score of 0.29 beat Windtree Therapeutics' score of 0.00 indicating that IM Cannabis is being referred to more favorably in the news media.

Company Overall Sentiment
Windtree Therapeutics Neutral
IM Cannabis Neutral

Windtree Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. Windtree Therapeutics' return on equity of -207.34% beat IM Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
IM Cannabis -27.65%-585.96%-39.96%

Windtree Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market. Comparatively, IM Cannabis has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by company insiders. Comparatively, 5.9% of IM Cannabis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

IM Cannabis beats Windtree Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Windtree Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WINT vs. The Competition

Export
MetricWindtree TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$810K$3.37B$6.49B$11.98B
Dividend YieldN/A2.32%2.67%5.57%
P/E Ratio0.0019.6523.8524.45
Price / SalesN/A312.51572.24136.74
Price / CashN/A120.3643.2054.62
Price / Book0.028.3210.666.80
Net Income-$1.79M$23.89M$3.56B$337.76M
7 Day PerformanceN/A0.94%0.05%2.08%
1 Month PerformanceN/A-1.16%0.37%3.16%
1 Year PerformanceN/A41.51%22.73%27.78%

Windtree Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WINT
Windtree Therapeutics
N/A$0.02
+28.6%		N/A-98.0%$810KN/AN/A30
VCNX
Vaccinex
N/A$0.84
-16.4%		N/A+36.8%$2.17M$388KN/A40
SLXN
Silexion Therapeutics
1.1462 of 5 stars		$4.99
+0.2%		N/A-97.7%$2.09MN/AN/AN/A
CANF
Can-Fite BioPharma
1.7953 of 5 stars		$3.16
-2.5%		$42.50
+1,245.4%		-87.0%$2.07M$405KN/A8
ELAB
PMGC
0.25 of 5 stars		$1.68
-5.1%		N/A-99.2%$2.05M$590KN/A18

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:WINT) was last updated on 6/12/2026 by MarketBeat.com Staff.
From Our Partners
Do NOT Buy SpaceX – Do This Instead
SpaceX is set to go public as soon as June 11, with OpenAI and Anthropic likely to follow. Whitney Tilson - Ha...
Stansberry Research | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
BUY THIS: Claim a backdoor stake in SpaceX
There may be a way to claim pre-IPO exposure to SpaceX before it ever hits public markets - using a simple tra...
Chaikin Analytics | Sponsoredtc pixel
Trump’s secret China deal
Trump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...
Porter & Company | Sponsoredtc pixel
Tesla. SolarCity. Twitter. This $4 stock is next.
Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel